| | 127254-12-0 Basic information More.. |
| Product Name: | Sitafloxacin | | Synonyms: | spifloxacin;7-[(4S)-4-Amino-6-azaspiro[2.4]heptan-6-yl]-8-chloro-6-fluoro-1-[(2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;3-Quinolinecarboxylic acid, 7-[(7S)-7-aMino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-;Sitafloxacin anhydrous;7-((S)-7-Amino-5-azaspiro[2.4]heptan-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4;Sitafloxacfn;Sitfloxacfn;Sitafloxacin-d4 | | CAS: | 127254-12-0 | | MF: | C19H18ClF2N3O3 | | MW: | 409.81 | | EINECS: | 1308068-626-2 | | Mol File: | 127254-12-0.mol |  |
Use
As a class, the major adverse events for fluoroquinolones are cardiac arrhythmia (due to QT interval 622 Shridhar Hegde and Michelle Schmidt prolongation), major phototoxicity, CNS disturbances (seizures, dizziness, and headaches), and tendonitis. The GI side effects, common to most antimicrobials, include Clostridium difficile-associated diarrhea (CDAD) and alterations in glucose homeostasis. From the clinical safety profile of sitafloxacin (1,059 patients receiving either 50 mg b.i.d. or 100 mg b.i.d.), about a third of patients experienced an adverse event with the most common being diarrhea, liver enzyme elevations, and headaches; however, the risk of QT prolongation, hypoglycemia, and hepatotoxicity were all considered to be low. Phototoxicity appears to be the limiting toxicity, particularly in non-Asian patients.
- Sitafloxacin USP/EP/BP
-
- $1.10
- 2026-08-20
- CAS:127254-12-0
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
- Sitafloxacin
-
- $35.00
- 2026-06-02
- CAS:127254-12-0
- Purity: 99.65%
- Supply Ability: 10g
|
|
127254-12-0
Recommend Suppliers |
|